About
Director since March 2019. CEO of ORIC Pharmaceuticals since May 2018; former CFO of Ignyta and investor at TPG Capital. Chairman of the board of Bright Peak Therapeutics.
Roles
4D Molecular Therapeutics, Inc.
Director · Current role
2019–present
Director Compensation
FY 2025
Fees earned or paid in cash
$65,000
Also at 4D Molecular Therapeutics, Inc.